Sugi Predict

Sugi Predict / Compounds / SCHEMBL55573

SCHEMBL55573

SCHEMBL55573

CC(C)(C)OC(=O)N[C@H]1c2ccccc2C[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ EPHX2 P34913 1/20 0.50
▸ MMP9 P14780 5/20 0.48
▸ MMP1 P03956 4/20 0.48
▸ MMP2 P08253 4/20 0.48
▸ MMP8 P22894 4/20 0.48
▸ NAMPT P43490 1/20 0.46
▸ P2RX7 Q99572 1/20 0.46
▸ PSEN1 P49768 1/20 0.46
▸ PSEN2 P49810 1/20 0.46
▸ APH1B Q8WW43 1/20 0.46
▸ NCSTN Q92542 1/20 0.46
▸ APH1A Q96BI3 1/20 0.46
▸ PSENEN Q9NZ42 1/20 0.46
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25730272 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL29922190 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL29502115 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL57180 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL5432481 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL56008 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL29381250 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL57241 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL22787577 1.00 MEN1 (0.52) MEN1ALDH1A1KMT2AEPHX2MMP9
SCHEMBL9680488 0.88 EPHX2 (0.47) MEN1ALDH1A1KMT2AEPHX2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 — — US disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 — — EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 — — US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 — — US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 — — US disclosed
WO-2023166303-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-09-07 — — WO disclosed
EP-4208442-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 — — EP disclosed
US-11192877-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2021-12-07 — — US disclosed
WO-2020012334-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2020-01-16 — — WO disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
US-20100137397-A1 Chemical Compounds ASTRAZENECA AB (SE) 2010-06-03 — — US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 — — US disclosed
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity BIRCH ALAN MARTIN 2009-05-14 — — US disclosed
EP-1658067-B1 INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2008-11-12 — — EP disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 — — EP disclosed
EP-1658069-B1 HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2008-07-30 — — EP disclosed
US-20080064691-A1 Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity ASTRAZENECA AB (SE) 2008-03-13 — — US disclosed
US-20080064691-A1 Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity ASTRAZENECA AB (SE) 2008-03-13 — — US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 MEN1 1126/4885ALDH1A1 87/4885KMT2A 761/4885
US-20240067614-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, CXCR2 MEN1 661/4885ALDH1A1 478/4885KMT2A 4448/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 MEN1 2336/4885ALDH1A1 38/4885KMT2A 3129/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI MEN1 699/4885ALDH1A1 63/4885KMT2A 3787/4885
US-20100137397-A1 Chemical Compounds PYGL, PYGM, GYS2 MEN1 2132/4885ALDH1A1 604/4885KMT2A 3303/4885
US-20080064691-A1 Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity PYGL, PYGM, GYS1 MEN1 3606/4885ALDH1A1 3170/4885KMT2A 2336/4885
US-11192877-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof XDH, HTR1D, RXFP1 MEN1 1434/4885ALDH1A1 332/4885KMT2A 2490/4885
US-20090124682-A1 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity PYGL, PYGM, GYS1 MEN1 2657/4885ALDH1A1 1178/4885KMT2A 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.